

**In the claims:**

Please cancel claims 4, 10-11, 38 and 39 without prejudice or disclaimer.

Please replace the pending claims with the following claims:

- BT
- Sub C1
1. (Currently Amended) A method to achieve MHC-class II mediated immunomodulation in a human with an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- $\gamma$  inducible Class II transactivator expression, the method comprising administering to said mammal at least one statin selected from the group consisting of compactin, atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, cerivastatin, and simvastatin, in an amount effective to modulate MHC class II expression in said mammal, wherein the an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- $\gamma$  inducible Class II transactivator expression is selected from the group consisting of psoriasis, Type I diabetes, multiple sclerosis, rheumatoid arthritis and atherosclerosis.
  2. (Currently Amended) A method to achieve MHC-class II mediated immunosuppression in a human with an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- $\gamma$  inducible Class II transactivator expression, the method comprising administering to said mammal at least one statin selected from the group consisting of compactin, atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, cerivastatin, and simvastatin, in an amount effective to suppress MHC class II expression in said mammal, wherein the an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- $\gamma$  inducible Class II transactivator expression is selected from the group consisting of psoriasis, Type I diabetes, multiple sclerosis, rheumatoid arthritis and atherosclerosis.
  3. (Currently Amended) A method to achieve MHC-class II mediated anti-inflammatory effect in a human with an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- $\gamma$  inducible Class II transactivator expression, the method comprising administering to said mammal at least one statin selected from the group consisting of compactin, atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, cerivastatin, and simvastatin, in an amount effective to suppress MHC class II expression in said mammal, wherein the an MHC Class II-mediated inflammatory or autoimmune disorder characterized by

①  
B1  
Cpdt  
IFN-γ inducible Class II transactivator expression is selected from the group consisting of psoriasis, Type I diabetes, multiple sclerosis, rheumatoid arthritis and atherosclerosis.

---

B2  
5. (Currently Amended) The method of claims 1, 2 or 3, wherein said human does not suffer from hypercholesterolaemia.

---

6. The method of claims 1, 2 or 3, wherein said amount is effective to specifically modulate IFN-γ inducible MHC class II expression.

15. (Previously Amended) The method of claims 1, 2 or 3, wherein said statin is administered in the absence of any other immunosuppressive agents.

16. (Previously Amended) The method of claims 1, 2 or 3, wherein said amount is between about 10 to about 80 mg per day.

17. (Previously Amended) The method of claims 1, 2 or 3, wherein said amount is between about 20 to about 40 mg per day.

---

B3  
18. (Currently Amended) The method of claims 1, 2 or 3, wherein said administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; or topical, nasal, oral, ocular or optic delivery.

---

19. The method of claims 1, 2 or 3, wherein said administration is made daily.

20. The method of claim 2 or 3, wherein the immunosuppression or anti-inflammatory effect is the result of repression of T lymphocyte activation.

---

B4  
35. (Currently Amended) A method of treating a patient afflicted with an autoimmune disease characterized by IFN-γ inducible Class II transactivator expression, comprising administering to said patient a compound that inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA reductase) in an amount effective to treat said disease, wherein the autoimmune

B4  
contd

disorder characterized by IFN- $\gamma$  inducible Class II transactivator expression is selected from the group consisting of psoriasis, Type I diabetes, multiple sclerosis, rheumatoid arthritis and atherosclerosis.

---

36. The method of claim 35 wherein said compound has a therapeutically insignificant lipid-lowering effect and suppresses MHC Class II expression.

---

B5  
D

37. (Currently Amended) A method of treating a patient suffering from an autoimmune disease or condition characterized by IFN- $\gamma$  inducible Class II transactivator expression comprising:

administering to said patient at least one compound, capable of measurable HMG-CoA reductase inhibition and inhibition of MHC Class II expression in said patient, in an amount effective to treat such autoimmune disease or condition, wherein the autoimmune disease or condition characterized by IFN- $\gamma$  inducible Class II transactivator expression is selected from the group consisting of psoriasis, Type I diabetes, multiple sclerosis, rheumatoid arthritis and atherosclerosis.

---